These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 20025567)

  • 21. Anti-tumour activity of zoledronic acid.
    Clézardin P
    Cancer Treat Rev; 2005; 31 Suppl 3():1-8. PubMed ID: 16225995
    [TBL] [Abstract][Full Text] [Related]  

  • 22. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
    Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
    Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.
    Jagdev SP; Coleman RE; Shipman CM; Rostami-H A; Croucher PI
    Br J Cancer; 2001 Apr; 84(8):1126-34. PubMed ID: 11308265
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid.
    Ullén A; Lennartsson L; Harmenberg U; Hjelm-Eriksson M; Kälkner KM; Lennernäs B; Nilsson S
    Acta Oncol; 2005; 44(6):644-50. PubMed ID: 16165924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Delivery of zoledronic acid encapsulated in folate-targeted liposome results in potent in vitro cytotoxic activity on tumor cells.
    Shmeeda H; Amitay Y; Gorin J; Tzemach D; Mak L; Ogorka J; Kumar S; Zhang JA; Gabizon A
    J Control Release; 2010 Aug; 146(1):76-83. PubMed ID: 20462513
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bisphosphonates modulate vital functions of human osteoblasts and affect their interactions with breast cancer cells.
    Kaiser T; Teufel I; Geiger K; Vater Y; Aicher WK; Klein G; Fehm T
    Breast Cancer Res Treat; 2013 Jul; 140(1):35-48. PubMed ID: 23807419
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bisphosphonates as anticancer therapy for early breast cancer.
    Mahtani R; Jahanzeb M
    Clin Breast Cancer; 2010 Oct; 10(5):359-66. PubMed ID: 20920980
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined Use of Zoledronic Acid Augments Ursolic Acid-Induced Apoptosis in Human Osteosarcoma Cells through Enhanced Oxidative Stress and Autophagy.
    Wu CC; Huang YF; Hsieh CP; Chueh PJ; Chen YL
    Molecules; 2016 Nov; 21(12):. PubMed ID: 27916903
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extracellular Ca(2+)-dependent enhancement of cytocidal potency of zoledronic acid in human oral cancer cells.
    Inoue S; Arai N; Tomihara K; Takashina M; Hattori Y; Noguchi M
    Eur J Pharmacol; 2015 Aug; 761():44-54. PubMed ID: 25934567
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer.
    Morgan C; Lewis PD; Jones RM; Bertelli G; Thomas GA; Leonard RC
    Acta Oncol; 2007; 46(5):669-77. PubMed ID: 17562444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased anti-tumour effects of doxorubicin and zoledronic acid in prostate cancer cells in vitro: supporting the benefits of combination therapy.
    Clyburn RD; Reid P; Evans CA; Lefley DV; Holen I
    Cancer Chemother Pharmacol; 2010 Apr; 65(5):969-78. PubMed ID: 19730863
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients.
    Odri GA; Dumoucel S; Picarda G; Battaglia S; Lamoureux F; Corradini N; Rousseau J; Tirode F; Laud K; Delattre O; Gouin F; Heymann D; Redini F
    Cancer Res; 2010 Oct; 70(19):7610-9. PubMed ID: 20841471
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The bisphosphonate zoledronic acid induces cytotoxicity in human myeloma cell lines with enhancing effects of dexamethasone and thalidomide.
    Ural AU; Yilmaz MI; Avcu F; Pekel A; Zerman M; Nevruz O; Sengul A; Yalcin A
    Int J Hematol; 2003 Dec; 78(5):443-9. PubMed ID: 14704038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.
    Cirak Y; Varol U; Atmaca H; Kisim A; Sezgin C; Karabulut B; Uzunoglu S; Uslu R; Karaca B
    BJU Int; 2012 Dec; 110(11 Pt C):E1147-54. PubMed ID: 22882676
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer.
    Duivenvoorden WC; Vukmirović-Popović S; Kalina M; Seidlitz E; Singh G
    Br J Cancer; 2007 May; 96(10):1526-31. PubMed ID: 17437017
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE).
    Facchini G; Caraglia M; Santini D; Nasti G; Ottaiano A; Striano S; Maiolino P; Ruberto M; Fiore F; Tonini G; Budillon A; Iaffaioli RV; Zeppetella GL
    J Exp Clin Cancer Res; 2007 Sep; 26(3):307-12. PubMed ID: 17987788
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Augmentation of the cytotoxic effects of nitrogen-containing bisphosphonates in hypoxia.
    Minegaki T; Koiki S; Douke Y; Yamane C; Suzuki A; Mori M; Tsujimoto M; Nishiguchi K
    J Pharm Pharmacol; 2018 Aug; 70(8):1040-1047. PubMed ID: 29761837
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bisphosphonates and their impact on disseminated tumor cells in early stage breast cancer.
    Li J; Rugo HS
    Breast Dis; 2011; 33(2):83-92. PubMed ID: 22142661
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines.
    Kimura S; Kuroda J; Segawa H; Sato K; Nogawa M; Yuasa T; Ottmann OG; Maekawa T
    Int J Hematol; 2004 Jan; 79(1):37-43. PubMed ID: 14979476
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide.
    Abeltino M; Bonomini S; Bolzoni M; Storti P; Colla S; Todoerti K; Agnelli L; Neri A; Rizzoli V; Giuliani N
    Exp Hematol; 2011 Jan; 39(1):55-65. PubMed ID: 20977926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.